Open Orphan PLC Upcoming Investor Events
08 Juillet 2020 - 8:00AM
RNS Non-Regulatory
TIDMORPH
Open Orphan PLC
08 July 2020
08 July 2020
RNS REACH
Open Orphan Plc
("Open Orphan" or the "Company")
Upcoming Investor Events
Open Orphan plc (ORPH), a rapidly growing specialist CRO
pharmaceutical services company which is the world leader in the
testing of vaccines and antivirals using human challenge study
models is delighted to be attending and presenting at a series of
investor events from the 9(th) to 11(th) July 2020.
Cathal Friel, Open Orphan's Chief Executive Officer, will be in
attendance for all of the events and will be presenting to update
existing and potential investors on the Company's business plans
for 2020-2021.
No new material information will be disclosed at any event.
A full schedule of the upcoming events is as follows:
Event Date/Time Location
Hardman & Co Investor July 9(th) 2020 / 15:00 Virtual Event, further
Forum Webinar - 16:30 information and registration
here: Link
Proactive Investors July 9(th) 2020 / 18:00 Virtual Event, further
One2One Investor Forum - 20:00 information and registration
here: Link
------------------------ ------------------------------
Mello Virtual - Investing July 11(th) 2020 / Virtual Event, further
in the New World 9:00 - 17:00 information and registration
here: Link
------------------------ ------------------------------
For further information please contact
+353 (0)1 644
Open Orphan plc 0007
Cathal Friel, Executive Chairman
Arden Partners plc (Nominated Adviser +44 (0)20 7614
and Joint Broker) 5900
John Llewellyn-Lloyd / Benjamin Cryer
/ Dan Gee-Summons
+44 (0) 20 7220
finnCap plc (Joint Broker) 500
Geoff Nash / James Thompson/ Richard
Chambers
Davy (Euronext Growth Adviser and Joint +353 (0)1 679
Broker) 6363
Anthony Farrell
+44 (0)20 3757
Camarco (Financial PR) 4980
Tom Huddart / Hugo Liddy
Notes to Editors - Open Orphan:
Open Orphan is a rapidly growing niche CRO pharmaceutical
services group which is a world leader in the testing of vaccines
and antivirals through the use of human challenge clinical trials.
Conducted from Europe's only 24-bedroom quarantine clinic with
onsite virology providing individually isolated rooms and connected
to our specialist laboratory facility. Which offers highly
specialised virology and immunology laboratory services to support
pre-clinical and clinical respiratory drug, antiviral, and vaccine
discovery and development. Reliable laboratory analysis underpinned
by scientific expertise is essential when processing and analysing
clinical samples. Robust quality processes support our team of
scientists in the delivery of submission ready data.
The Group has a leading portfolio of 8 viral challenge study
models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD
viral challenge models. As announced in early March, Open Orphan is
rapidly advancing a number of Coronavirus challenge study models
and expects to be helping many COVID-19 vaccine development
companies to test their vaccines. No other company in the world has
such a portfolio, with only two competitors globally having 1
challenge study model each. In June 2020 hVIVO COVID Clear Test was
launched, the most accurate antibody test available to UK
employers, helping them to get their people back to work.
Open Orphan comprises of two commercial specialist CRO services
businesses, hVIVO and Venn Life Sciences , and is developing an
early stage orphan drug genomics data platform business. This
platform captures valuable genetic data from patient populations
with specific diseases with designated orphan drug status and
incorporating AI tools. In June 2019, Open Orphan acquired
AIM-listed Venn Life Sciences Holdings plc in a reverse take-over
and in January 2020 it completed the merger with hVIVO plc. Venn,
as an integrated drug development consultancy, offers CMC
(chemistry, manufacturing and controls), preclinical, Phase I &
II clinical trials design and execution. The merger with hVIVO
created a European full pharma services group broadening the
Group's customer base and with complementary specialist CRO
services, widened the range of the Group's service offerings.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEAFXXELEEEAA
(END) Dow Jones Newswires
July 08, 2020 02:00 ET (06:00 GMT)
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024